Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
- 31 October 1994
- journal article
- Published by Elsevier in International Journal of Immunopharmacology
- Vol. 16 (10) , 805-816
- https://doi.org/10.1016/0192-0561(94)90054-x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cellsInternational Journal of Immunopharmacology, 1993
- Inhibition of interleukin-1 (IL-1) and tumor necrosis factor (TNF) production by pyridinyl imidazole compounds is independent of cAMP elevating mechanismsInflammation Research, 1993
- Inhibition of CD44, CD45 and LFA-3 mediated cytokine release from human monocytes by SK&F 86002 and pentoxifyllineInternational Journal of Immunopharmacology, 1993
- SK&F 86002 Inhibits Tumor Necrosis Factor Formation and Improves Survival in Endotoxemic RatsJournal of Cardiovascular Pharmacology, 1991
- TNF in Pathophysiology: Biosynthetic RegulationJournal of Investigative Dermatology, 1990
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990
- Tumor Necrosis Factor and Interleuktn-1 in the Serum of Children with Severe Infectious PurpuraNew England Journal of Medicine, 1988
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationNew England Journal of Medicine, 1988
- ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASEThe Lancet, 1987
- Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxinNature, 1984